Systemic Sclerosis-Associated Ild
Patients with progressing SSc-ILD should be seen ‘every 3 to 6 months’
SAN DIEGO — Rheumatologists should stratify patients with systemic sclerosis-associated interstitial lung disease into phenotypes in order to closely monitor those with progressing disease, according to a speaker here.
Certain elevated biomarkers aid in diagnosis of systemic sclerosis-related ILD
For diagnosing systemic sclerosis-related ILD, Krebs von den Lungen-6, surfactant protein-D and interleukin-8 in blood/bronchoalveolar lavage fluid samples were found to be “reliable biomarkers,” according to results published in Thorax.
Proton pump inhibitors improve survival in systemic sclerosis-associated ILD
The use of proton pump inhibitors improves overall and progression-free survival in patients with systemic sclerosis-associated interstitial lung disease, according to data published in Rheumatology.
Gastroprotective, promotility agents fail to prevent systemic sclerosis-associated ILD
Gastroprotective and promotility agents do not appear to prevent clinically apparent systemic sclerosis-associated interstitial lung disease, according to results of a large retrospective cohort study.
Immunosuppressants remain ‘cornerstone’ therapy for CTD-ILD as drug options emerge
Although immunosuppressives remain the cornerstone for managing underlying interstitial lung disease in connective tissue diseases, new drug approvals could help shift the treatment paradigm, according to data presented here.
Sustained reduction in lung function decline over longer-term with nintedanib in SSc-ILD
In the SENSCIS-ON trial, two-thirds of patients with systemic sclerosis-associated interstitial lung disease who continued nintedanib after completion of the SENSCIS trial maintained stable lung function or had improvement in lung function.